![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Court Rules Taiwanese Company Infringed on Supernus’ Oxtellar Patents
Court Rules Taiwanese Company Infringed on Supernus’ Oxtellar Patents
August 22, 2017
A New Jersey federal court ruled that a Taiwanese firm infringed on patents held by Maryland-based drugmaker Supernus.
The court ruled that TWi Pharmaceuticals infringed on three of Supernus’ patents in its ANDA for a generic version of Oxtellar (oxcarbazepine), used to treat central nervous system diseases such as epilepsy.
The ruling, issued after a four-day bench trial, confirmed the validity of the three patents.
U.S. District Judge Renee Marie Bumb ordered the companies to jointly submit a proposed form of final judgment consistent with the order by Aug. 25.
Upcoming Events
-
21Oct